AI assistant
Gubra A/S — Director's Dealing 2025
Nov 10, 2025
6302_rns_2025-11-10_1b99c723-e393-45df-a8a1-cb1f71016ff6.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Regulatory press release 10 November 2025 17:29:00 CET
==> picture [90 x 43] intentionally omitted <==
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A /S' shares
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.
==> picture [455 x 419] intentionally omitted <==
----- Start of picture text ----- Details of the person discharging managerial responsibilities/person closely1.associateda) Name Monika Lessl2. Reason for the notificationa) Position/status Chairman in Gubrab) Initial notification/ Amendment Initial notificationDetails of the issuer, emission allowance market participant, auction platform,3.auctioneer or auction monitora) Name Gubra A/Sb) LEI 254900T17RRFZONO6W534.1 Details of the transaction(s):SharesDescription of the financial instrument, type ofa) instrumentIdentification codeISIN DK0062266474b) Nature of the transaction PurchasePrice(s) Volume(s)c) Price(s) and volume(s)DKK 392.62 379----- End of picture text -----
Gubra Hørsholm Kongevej 11B 2970 Hørsholm
Regulatory press release 10 November 2025 17:29:00 CET
==> picture [90 x 43] intentionally omitted <==
==> picture [455 x 123] intentionally omitted <==
----- Start of picture text ----- Average price per share: DKKAggregated information392.62d) — Aggregated volumeTotal number of shares: 379— PriceTotal price: DKK 148,801e) Date of the transaction 7 November 2025f) Place of the transaction NASDAQ Copenhagen----- End of picture text -----
Contacts at Gubra
Media: Sofia Pitt Boserup ([email protected], +45 4188 9586) Investors: Kristian Borbos ([email protected], +45 3080 8035) and Emma Jappe Lange ([email protected], +45 5361 6755)
About Gubra
Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 275 employees and in 2024 revenue of DKK 266 million. See www.gubra.dk for more information.
Gubra Hørsholm Kongevej 11B 2970 Hørsholm